NetworkNewsBreaks – BiondVax Pharmaceuticals Ltd
Post# of 122
(Total Views: 184)
Posted On: 12/29/2022 3:20:30 PM
NetworkNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Well-Positioned to Bring Innovative Therapies to Market
BiondVax (NASDAQ: BVXV) is focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. “BiondVax is developing a pipeline of nanosized antibody (‘NanoAb’) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, psoriasis, asthma, psoriatic arthritis, and wet macular degeneration. The company currently collaborates with the prestigious Max Planck Institute for Multidisciplinary Sciences (‘MPG’) and the University Medical Center Göttingen (‘UMG’), both in Germany,” a recent article reads. “BiondVax is targeting a massive, validated, addressable market with a pipeline of de-risked NanoAbs with a lead candidate to treat COVID-19 as a self-administered inhaled therapy that has a strong competitive edge. With seasoned scientific leadership and state-of-the-art laboratories and GMP biologics manufacturing facility, the company is well-positioned to bring innovative therapies to market with unique large pharma competencies. Key catalysts for BiondVax are expected in 2022 and 2023.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
BiondVax (NASDAQ: BVXV) is focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. “BiondVax is developing a pipeline of nanosized antibody (‘NanoAb’) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, psoriasis, asthma, psoriatic arthritis, and wet macular degeneration. The company currently collaborates with the prestigious Max Planck Institute for Multidisciplinary Sciences (‘MPG’) and the University Medical Center Göttingen (‘UMG’), both in Germany,” a recent article reads. “BiondVax is targeting a massive, validated, addressable market with a pipeline of de-risked NanoAbs with a lead candidate to treat COVID-19 as a self-administered inhaled therapy that has a strong competitive edge. With seasoned scientific leadership and state-of-the-art laboratories and GMP biologics manufacturing facility, the company is well-positioned to bring innovative therapies to market with unique large pharma competencies. Key catalysts for BiondVax are expected in 2022 and 2023.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)